Browse Peptide Current coverage filtered to injection delivery.
43 articles
Tesamorelin side effects are usually local and manageable. The bigger question is whether daily injections, glucose monitoring, and the HIV-lipodystrophy-approved label fit your actual needs.
TB-500's timing depends on one crucial distinction: the marketed fragment differs from the full thymosin beta-4 in human trials. Here's what the research shows—and why that separation changes everything for your protocol.
You can stop guessing at BPC-157 dosage. Real answers live in the current trials and published data—but route matters more than any single number. Here's the practical breakdown.
Epitalon dosing clarity comes from understanding what the real human routines show—short courses, route-specific protocols, and why one settled U.S. standard still doesn't exist.
The approved PT-141 injection (Vyleesi) delivers on-demand libido benefit with a real tradeoff: meaningful nausea, flushing, headache, and blood-pressure cautions. Know the clear safety profile before committing.
The AOD-9604 dosage question is clearest when you stick to clinical evidence: once-daily oral regimens in real human trials, followed by a larger study that changed everything. Here's what actually moved the needle.
Tirzepatide is the settled, approved option you can start using today. Retatrutide shows bigger weight-loss potential but remains investigational. Your pick depends on whether you want certainty now or the highest ceiling later.
Master GHK-Cu dosage by treating topical and injectable as two different games. Topicals win on concentration and routine fit; injectables face tighter scrutiny. Route first, always.
Tesamorelin is a straightforward once-daily injection, but EGRIFTA WR and EGRIFTA SV use different strengths and mixing routines. The key insight: this is labeled for HIV-related abdominal fat, not general weight loss.
PT-141 works: one Vyleesi injection, proven desire improvement, and clear dosing rules. But success depends on nausea tolerance and whether the timing actually fits your life.
Both peptides raise growth hormone through different signals and vastly different evidence histories. Sermorelin has authentic medical grounding; ipamorelin has a cleaner selectivity story but a much thinner human record.
New April 2026 prescribing data shows how Vyleesi and Addyi are reaching similar specialists through very different access routes—a gap that could shape your options.